In a summary, TMPO‐AS1 promotes HCC through sponging miR‐329‐3p to upregulate FOXK1 and activate AKT/mTOR signaling pathway, which was the first to illustrate the potential of TMPO‐AS1 as a therapeutic target in HCC. Here, TMPO is linked to hepatocellular carcinoma.